CytomX Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
CytomX Therapeutics, Inc. holds 14 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 14 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include CYTOMX and PROBODY. The owner is based in South San Francisco, CA.
151 Oyster Point Blvd, Suite 400
South San Francisco, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
CytomX Therapeutics, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does CytomX Therapeutics, Inc. have?
CytomX Therapeutics, Inc. has 14 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 10 abandoned.
What trademark classes does CytomX Therapeutics, Inc. file in?
CytomX Therapeutics, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are CytomX Therapeutics, Inc.'s most well-known trademarks?
CytomX Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as CYTOMX and PROBODY. These are among 3 currently registered trademarks in the portfolio.
What is CytomX Therapeutics, Inc.'s trademark registration success rate?
CytomX Therapeutics, Inc. has a 23% trademark registration rate, with 3 out of 13 resolved applications resulting in successful registration. Currently, 1 application is pending review.